Neogap Therapeutics has received regulatory approval from the Swedish Medical Products Agency to administer the full dose of its investigational cell therapy to all patients in its ongoing phase 1 and 2 trial for advanced colorectal cancer. The approval allows for a revised study protocol that removes the initial dose-escalation step, allowing all participants to […]
The post Neogap receives approval to administer full dose in cell therapy trial for colorectal cancer appeared first on Pharmafile.
